Abcellera Biologics Inc ABCL

$12.46 -0.04 (-0.32%)

Valuation

Market cap
3,832,638,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,912,300
Avg volume
4,350,442
Day's range
$11.91 – $12.96
Shares out
306,611,000
Stochastic %K
55%
Beta
1.59
Analysts
Strong Buy
Price target
$17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Planetpaprika Nov 11, 1:00 PM
$ABCL Stifel Nicolaus raised its price target on AbCellera Biologics from $9 to $14 and maintained a Buy rating. Analyst sentiment is broadly positive: ABCL has a “Moderate Buy” consensus rating and an average price target of $16.33. AbCellera beat quarterly estimates, reporting a $0.13-per-share loss versus the $0.17 consensus and revenue of $10.64 million versus $8.41 million expected, though it remains unprofitable.
0 replies
Stockingtrade Nov 11, 11:49 AM
$ABCL Healthcare conference presentation this morning, just after great earnings report and new targets dropping? I'm thinking today is going to be a big day, might be the last chance to buy in below $13!
0 replies
flymetothemoon2 Nov 11, 9:56 AM
$ABCL “Biotech stocks are now where semiconductor stocks were in 2024.” That is an intriguing claim from investor Justin Spittler. I agree that biotech could emerge as the next leading industry I think the biotech industry is likely to enter an important growth phase ahead. AI drug development, more efficient clinical trials, and the race among global pharmaceutical companies to secure technology are clearly developments worth watching. But one thing is clear. The leaders of the next biotech bull market will not be companies with AI in their name, but companies that turn AI and science and technology into actual treatments and profits.
0 replies
flymetothemoon2 Nov 11, 9:41 AM
$ABCL $ABCL — Today could be worth watching. 👀 AbCellera presents at the Stifel Healthcare Conference today at 8 AM ET. Fresh off its Q3 update: ~$890M in available liquidity, positive Phase 2 data for ABCL635, and late-stage development planned for 2027. The balance sheet looks stronger. The pipeline is expanding. But the real question is execution. I'll be listening for any new details on ABCL635, clinical timelines, and capital allocation. this is a company worth paying attention to.
1 replies
flymetothemoon2 Nov 11, 8:50 AM
$ABCL The progress is amazing. It is a completely different company compared to 6 month ago. I have never seeing a Company derisking so fast.
1 replies
flymetothemoon2 Nov 11, 8:43 AM
$ABCL Another Upgrade this morning by Goldman Sachs from $13 to $14.00 maintains a BUY HOLD Just finished the $ABCL Q3 earnings call. it’s unbelievable the number of analysts who asked the same question said differently regarding ABCL992. It’s a stronger formula that requires less frequent dosing and prevents the competition from eating their lunch. Don’t sleep on it
0 replies
DeMampCamp Nov 10, 11:08 PM
$ABCL ER was fantastic last night, today was a product of the overall market sentiment thanks to the hotter than expected CPI data. I fully expect us to be over $13 in the coming days, I also think we'll test $15 again
1 replies
Stockingtrade Nov 10, 9:13 PM
$ABCL Short interest at 29m, as of Oct 30, and stock dropped since then, so may even be higher now. As it stands, 8.5 days to cover means entering squeeze territory for shorts - should be a fun few weeks for longs!
0 replies